Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?
Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?
复制标题
DOI：
10.1186/ar2177
复制
发表时间：
2007
影响因子：
4.9
通讯作者：
Emery P
中科院分区：
文献类型：
--
作者：
Ikeda K;Cox S;Emery P
为类风湿性关节炎患者提供更新、更昂贵的治疗方法已经使治疗方式发生了翻天覆地的变化。疾病缓解是所有新患者的目标。研究表明，肿瘤坏死因子(TNF)阻断药物和甲氨蝶呤的组合比单一治疗产生更好的结果；然而，使用受到成本和潜在副作用的限制。目前，抗肿瘤坏死因子治疗通常保留给那些传统的抗风湿药物治疗失败的患者。仍然存在的问题是，如果及早使用阻断肿瘤坏死因子的药物是否更好；通过优化疾病控制而直接和间接节省的医疗成本，抵消了高昂的直接成本；及早控制的好处超过了感染和恶性肿瘤风险的增加。
The availability of newer, and more expensive, therapies for patients with rheumatoid arthritis has changed treatment beyond recognition. Disease remission is the goal for all new patients. Studies have shown that a combination of tumour necrosis factor (TNF)-blocking drugs and methotrexate produces superior outcomes over monotherapy alone; however, use is limited by cost and potential side-effects. Currently, anti-TNF therapy is normally reserved for patients who have failed traditional disease-modifying anti-rheumatic drugs. The question that remains is whether TNF-blocking drugs are better used if given early; the high direct costs are countered by both direct and indirect savings in healthcare costs from optimal control of disease, and the benefits of early control outweigh the increased risk of infection and malignancy.
登录
查看更多内容
影响因子：
--
作者：
Keystone, EC;Kavanaugh, AF;Chartash, EK
通讯作者：
Chartash, EK
影响因子：
--
作者：
Gómez-Reino, JJ;Carmona, L;Montero, MD
通讯作者：
Montero, MD
影响因子：
--
作者：
Goekoop-Ruiterman, YPM;de Vries-Bouwstra, JK;Dijkmans, C
通讯作者：
Dijkmans, C
影响因子：
82.9
作者：
Diarra, Danielle;Stolina, Marina;Schett, Georg
通讯作者：
Schett, Georg
影响因子：
5.5
作者：
Kroesen, S;Widmer, AF;Hasler, P
通讯作者：
Hasler, P